Identifizierung von Biomarkern für die Prognose der Gemcitabin-Therapie beim Pankreaskarzinom: RNA-, DNA- und Immunhistochemische- Analysen
Identification of biomarkers for the prognosis in gemcitabine treated pancreatic cancer: RNA-, DNA- and immunhistochemical- analysis
von Christian Zimmer
Datum der mündl. Prüfung:2015-02-11
Erschienen:2015-02-06
Betreuer:Prof. Dr. Jürgen Brockmöller
Gutachter:Prof. Dr. Volker Ellenrieder
Gutachter:Prof. Dr. Margarete Schön
Dateien
Name:Dissertation_CZimmer_SUB.pdf
Size:2.31Mb
Format:PDF
Description:Medizinsche Dissertation
Zusammenfassung
Englisch
One aim of this study was to investigate the associations of genetic polymorphisms in the genes involved in gemcitabine pathways and the cinical outcome of patients with pancreatic ductal adenocarcinoma. A nucleoitide polymorphism in ENT1 (SLC29A1) gene, a transmembrane transporter of gemcitabine, had an influence on overall survival. Based on immunhistochemical analysis it could be shown, that patients with a high ENT1 protein expression benefits from a gemcitabin therapy.
Keywords: pankreatic cancer; gemcitabin treatment; ent1; genetic polymorphisms; nucleoside transporter
Schlagwörter: Gemcitabin; Pankreaskarzinom; ENT1; genetische Polymorphismen; Nukleosid Transporter